Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.

Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B.

Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26308. [Epub ahead of print]

PMID:
26175332
2.

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects.

Braeckman RA, Stirtan WG, Soni PN.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):143-148. Epub 2014 Dec 3.

3.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.

J Clin Lipidol. 2015 May-Jun;9(3):377-83. doi: 10.1016/j.jacl.2014.11.009. Epub 2014 Nov 29.

4.

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA.

Metab Syndr Relat Disord. 2015 Aug;13(6):239-47. doi: 10.1089/met.2014.0137. Epub 2015 Apr 20.

PMID:
25893544
5.

Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2015 Jan;35(1):45-51. doi: 10.1007/s40261-014-0252-8.

6.

Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.

Braeckman RA, Stirtan WG, Soni PN.

Drugs R D. 2014 Sep;14(3):159-64. doi: 10.1007/s40268-014-0053-9.

7.

Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2014 Jul;34(7):449-56. doi: 10.1007/s40261-014-0194-1.

PMID:
24760401
8.

Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects.

Braeckman RA, Stirtan WG, Soni PN.

Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22.

9.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005. Epub 2013 Aug 1.

PMID:
23992935
10.

Flux duality in nonlinear GMA systems: implications for metabolic engineering.

Marin-Sanguino A, Mendoza ER, Voit EO.

J Biotechnol. 2010 Sep 1;149(3):166-72. doi: 10.1016/j.jbiotec.2009.12.009. Epub 2009 Dec 14.

PMID:
20015458
11.

[Radiotherapy in dermatology].

Marín A, Vargas-Díez E, Cerezo L.

Actas Dermosifiliogr. 2009 Apr;100(3):166-81. Review. Spanish.

PMID:
19457302
12.

Metabolic Engineering with power-law and linear-logarithmic systems.

Marin-Sanguino A, Torres NV, Mendoza ER, Oesterhelt D.

Math Biosci. 2009 Mar;218(1):50-8. doi: 10.1016/j.mbs.2008.12.010. Epub 2009 Jan 11.

PMID:
19174172
13.

Optimization of biotechnological systems through geometric programming.

Marin-Sanguino A, Voit EO, Gonzalez-Alcon C, Torres NV.

Theor Biol Med Model. 2007 Sep 26;4:38.

14.

Ethyl-EPA in Huntington disease: potentially relevant mechanism of action.

Murck H, Manku M.

Brain Res Bull. 2007 Apr 30;72(2-3):159-64. Epub 2006 Nov 15. Review.

PMID:
17352940
15.

[Blood banks].

Marín-López A.

Rev Gastroenterol Mex. 2002 Oct;67 Suppl 2:S11-2. Spanish.

PMID:
12712844
16.

Practical implications of nutritional support during continuous renal replacement therapy.

Marin A, Hardy G.

Curr Opin Clin Nutr Metab Care. 2001 May;4(3):219-25. Review.

PMID:
11517356
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk